Results 51 to 60 of about 131,629 (255)
Changing therapeutic landscape - The last decade [PDF]
, 2011 Undoubtedly the most important event in the previous decade in lymphoma treatment was the establishment of immunotherapy as a prime modality. Addition of rituximab improves survival in almost every group of patients with CD20+ tumors. This has led to the
Aurer, Igor
core +1 more source
Combating cancer immunotherapy resistance: a nano‐medicine perspective
Cancer Communications, EarlyView.Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong +10 more
wiley +1 more source
Cancer Communications, EarlyView.Abstract Background Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of aggressive non‐Hodgkin's lymphoma with distinct clinical and molecular heterogeneity. DLBCL that arises in extranodal organs is particularly linked to poor prognosis. This study aimed to determine the clinical and molecular characteristics of extranodal involvement (
Si‐Yuan Chen +46 more
wiley +1 more source
Hematopoietic stem cell transplantation in B- and T-cell lymphoma [PDF]
, 2013 Huijgens, P.C. [Promotor]Mulder, C.J.J. [Promotor]Dongen, G.A.M.S.
Visser, O.
core +2 more sources
Cancer Communications, EarlyView.Abstract Background Overweight and obesity are known risk factors for cancer. The aim of this study was to investigate associations of body mass index (BMI) and waist circumference (WC) with incidence of 27 site‐specific cancers stratified by sex and menopausal status accounting for non‐linearity.
Seonghye Kim +7 more
wiley +1 more source
Chemistry &Biodiversity, Accepted Article.Objective: Cancer remains a global health challenge, necessitating new therapeutic options. Phytochemicals, with diverse chemical structures and biological activities, show promise as anticancer agents. This review explores key phytochemicals, their mechanisms, and their potential integration into cancer therapy.
Alaa A. A. Aljabali +11 more
wiley +1 more source
Sperm DNA methylome abnormalities occur both pre- and post-treatment in men with Hodgkin disease and testicular cancer. [PDF]
Clin Epigenetics, 2023 Chan D +7 more
europepmc +1 more source
A case of primary Hodgkin's lymphoma of the parotid gland. Case report and differentian diagnosis from Kuttner's Syndrom [PDF]
, 2018 We report a rare case of primary Hodgkin’s lymphoma (HL) of the submandibular gland, with initially diagnosis of Kuttner’s Syndrom. A 48 years old man was referred to our hospital foe evaluation of a submandibular mass.
Di Cello, P. +8 more
core
Clinical Pharmacology in Drug Development, EarlyView.Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana +8 more
wiley +1 more source
The management of Hodgkin's disease
Annals of Oncology, 1993 A 27-year-old female school teacher originally presented in March 1987 with a six month history of painless left cervical lymphadenopathy. She had no systemic symptoms and there were no other signs of disease on clinical examination but a chest radiograph showed non-bulky mediastinal adenopathy. An abdominal CT scan was normal. Biopsy confirmed nodular
Radford, J A +2 more
openaire +4 more sources